SEC EDGARJul 1$PGEN

Sabzevari Helen sold $2.0M of PGEN

Sabzevari Helen (President and CEO) sold 346,836 shares of PRECIGEN, INC. (PGEN) at $5.89 ($2.04M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Sabzevari Helen

Published Jul 1, 2026, 10:19 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PGEN

Neutral

high confidence

Mentioned

$PGEN

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

The newest fact is the CEO’s disclosed open-market sale size, price, and post-transaction holdings, but the 10b5-1 designation reduces interpretive weight.

Market read

This can marginally influence short-term sentiment/positioning, but it does not introduce new fundamentals in the provided text.

What to watch

Traders may over-weight insider sales; without changes to guidance, trial results, or financing terms, the filing is unlikely to reset valuation assumptions.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction disclosure for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralHigh confidence

Context

Precigen CEO Sabzevari Helen filed a Form 4 open-market sale of 346,836 shares at $5.89 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The disclosure is an open-market sale by the CEO, explicitly under a pre-arranged 10b5-1 plan, with no accompanying new operational/regulatory/financial catalyst in the text.

Market effects

Sector

Minimal; this is company-specific insider transaction data with no sector-wide regulatory/clinical/financing signal provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may be purely mechanical rather than a bearish view on fundamentals.

Key entities

issuer
PRECIGEN, INC.
Company whose CEO insider transaction is disclosed on Form 4.
insider
Sabzevari Helen
President and CEO who sold 346,836 shares at $5.8900/share.

Read at source ← All news

$PGENMedAI 8/10

Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings

Precigen (PGEN) shares dropped 26% after Inovio (INO) received FDA approval for Voceryq, a rival to Precigen's Papzimeos. Voceryq offers easier dosing, though Papzimeos showed stronger trial results. Precigen reports Q3 earnings on November 4, with analysts expecting $236M in 2026 revenue.

finance.yahoo.comNov 2

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

finance.yahoo.comNov 2

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.comOct 30

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

insidermonkey.comSep 29

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

prnewswire.comSep 21

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.comAug 21